PI3Kinase Inhibition in Hormone Receptor-Positive Breast Cancer

Derangement of the phosphatidylinositol-3 kinase (PI3K) pathway is implicated in several subtypes of breast cancers. Mutation or upregulation of PI3K enhances cancer cells’ survival, proliferation, and ability to metastasize, making it an attractive molecular target for systemic therapy. PI3K has fo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ajay Dhakal, Luna Acharya, Ruth O’Regan, Shipra Gandhi, Carla Falkson
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	PI3Kinase inhibitor hormone receptor positive breast cancer breast cancer Biology (General) QH301-705.5 Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/de52808cef934de585708bda5de0bea6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:de52808cef934de585708bda5de0bea6
record_format	dspace
spelling	oai:doaj.org-article:de52808cef934de585708bda5de0bea62021-11-11T17:18:00ZPI3Kinase Inhibition in Hormone Receptor-Positive Breast Cancer10.3390/ijms2221118781422-00671661-6596https://doaj.org/article/de52808cef934de585708bda5de0bea62021-11-01T00:00:00Zhttps://www.mdpi.com/1422-0067/22/21/11878https://doaj.org/toc/1661-6596https://doaj.org/toc/1422-0067Derangement of the phosphatidylinositol-3 kinase (PI3K) pathway is implicated in several subtypes of breast cancers. Mutation or upregulation of PI3K enhances cancer cells’ survival, proliferation, and ability to metastasize, making it an attractive molecular target for systemic therapy. PI3K has four isoforms, and several drugs targeting individual isoforms or pan-PI3K have been or are currently being investigated in clinical trials. However, the search for an effective PI3K inhibitor with a robust therapeutic effect and reasonable safety profile for breast cancer treatment remains elusive. This review focuses on the recently completed and ongoing clinical trials involving PI3K inhibitors as mono- or combination therapy in breast cancer. We review the salient findings of clinical trials, the therapeutic efficacy of PI3K inhibitors, and reported adverse effects leading to treatment discontinuation. Lastly, we discuss the challenges and potential opportunities associated with adopting PI3K inhibitors in the clinic.Ajay DhakalLuna AcharyaRuth O’ReganShipra GandhiCarla FalksonMDPI AGarticlePI3Kinase inhibitorhormone receptor positive breast cancerbreast cancerBiology (General)QH301-705.5ChemistryQD1-999ENInternational Journal of Molecular Sciences, Vol 22, Iss 11878, p 11878 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	PI3Kinase inhibitor hormone receptor positive breast cancer breast cancer Biology (General) QH301-705.5 Chemistry QD1-999
spellingShingle	PI3Kinase inhibitor hormone receptor positive breast cancer breast cancer Biology (General) QH301-705.5 Chemistry QD1-999 Ajay Dhakal Luna Acharya Ruth O’Regan Shipra Gandhi Carla Falkson PI3Kinase Inhibition in Hormone Receptor-Positive Breast Cancer
description	Derangement of the phosphatidylinositol-3 kinase (PI3K) pathway is implicated in several subtypes of breast cancers. Mutation or upregulation of PI3K enhances cancer cells’ survival, proliferation, and ability to metastasize, making it an attractive molecular target for systemic therapy. PI3K has four isoforms, and several drugs targeting individual isoforms or pan-PI3K have been or are currently being investigated in clinical trials. However, the search for an effective PI3K inhibitor with a robust therapeutic effect and reasonable safety profile for breast cancer treatment remains elusive. This review focuses on the recently completed and ongoing clinical trials involving PI3K inhibitors as mono- or combination therapy in breast cancer. We review the salient findings of clinical trials, the therapeutic efficacy of PI3K inhibitors, and reported adverse effects leading to treatment discontinuation. Lastly, we discuss the challenges and potential opportunities associated with adopting PI3K inhibitors in the clinic.
format	article
author	Ajay Dhakal Luna Acharya Ruth O’Regan Shipra Gandhi Carla Falkson
author_facet	Ajay Dhakal Luna Acharya Ruth O’Regan Shipra Gandhi Carla Falkson
author_sort	Ajay Dhakal
title	PI3Kinase Inhibition in Hormone Receptor-Positive Breast Cancer
title_short	PI3Kinase Inhibition in Hormone Receptor-Positive Breast Cancer
title_full	PI3Kinase Inhibition in Hormone Receptor-Positive Breast Cancer
title_fullStr	PI3Kinase Inhibition in Hormone Receptor-Positive Breast Cancer
title_full_unstemmed	PI3Kinase Inhibition in Hormone Receptor-Positive Breast Cancer
title_sort	pi3kinase inhibition in hormone receptor-positive breast cancer
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/de52808cef934de585708bda5de0bea6
work_keys_str_mv	AT ajaydhakal pi3kinaseinhibitioninhormonereceptorpositivebreastcancer AT lunaacharya pi3kinaseinhibitioninhormonereceptorpositivebreastcancer AT ruthoregan pi3kinaseinhibitioninhormonereceptorpositivebreastcancer AT shipragandhi pi3kinaseinhibitioninhormonereceptorpositivebreastcancer AT carlafalkson pi3kinaseinhibitioninhormonereceptorpositivebreastcancer
_version_	1718432149075394560

PI3Kinase Inhibition in Hormone Receptor-Positive Breast Cancer

Ejemplares similares